Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been assigned an average recommendation of "Buy" from the ten research firms that are covering the company, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $62.22.

Several brokerages have recently issued reports on JSPR. UBS Group reduced their price target on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Oppenheimer cut their price objective on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th.

Jasper Therapeutics Stock Up 1.7%

JSPR stock traded up $0.10 during midday trading on Friday, reaching $6.00. The company had a trading volume of 229,156 shares, compared to its average volume of 298,858. The firm has a market capitalization of $90.13 million, a PE ratio of -1.27 and a beta of 2.74. The stock has a 50 day moving average price of $4.62 and a 200 day moving average price of $9.44. Jasper Therapeutics has a fifty-two week low of $3.13 and a fifty-two week high of $26.84.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.24). Research analysts predict that Jasper Therapeutics will post -4.47 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its position in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after buying an additional 3,828 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter valued at approximately $223,000. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics during the first quarter worth approximately $46,000. Tema Etfs LLC bought a new stake in Jasper Therapeutics during the fourth quarter worth approximately $266,000. Finally, Rhumbline Advisers lifted its position in Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock worth $316,000 after purchasing an additional 1,652 shares during the period. Institutional investors and hedge funds own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.